Futibatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion clinical trials

A Phase 2 Study Evaluating Futibatinib (TAS-120) Plus Pembrolizumab in the Treatment of Advanced or Metastatic Urothelial Carcinoma

This study is looking at a new combination of medicines, futibatinib and pembrolizumab (Keytruda), for people with advanced bladder cancer. Researchers want to see if this treatment can shrink tumours or stop them from growing. It's a Phase 2 study, meaning it's focusing on how well the treatment works and its safety.